66
Participants
Start Date
December 31, 2015
Primary Completion Date
September 30, 2018
Study Completion Date
May 31, 2019
Rocuronium
rocuronium 0.6 mg/kg intravenously (1 mg/kg only in a case of a rapid sequence induction)
Cisatracurium
cisatracurium 0.15mg/kg intravenously
Nonspecific Neuromuscular Blockade reversal
neostigmine 0.03 mg/kg and atropine 0.02 mg/kg intravenously
Specific Neuromuscular Blockade reversal
Sugammadex intravenously aimed to reverse the neuromuscular blockade.According to neuromuscular blockade monitoring: at TOF - (train-of-four) 2m g/kg, if TOF 0 and PTC(post-tetanic count) 0-1 4mg/kg of sugammadex will be administered
maintaining the depth of neuromuscular blockade - rocuronium
repeated boluses of rocuronium 0.3 mg/kg will be administered to maintain the muscular blockage - according to TOF 0, PTC 0-1
maintaining the depth of neuromuscular blockade - cisatracurium
repeated boluses of cisatracurium 0.03 mg/kg will be administered to maintain the muscular blockage - according to TOFmaintaining of muscular relaxation TOF 1
University Hospital Brno - FN Brno, Brno
KDCHOT FN Brno
UNKNOWN
Brno University Hospital
OTHER